MedTrace Logo

A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors

NCT07466160 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 280

Last updated 2026-03-12

No results posted yet for this study

Summary

This study was designed to evaluate the efficacy and safety of 7MW3711 in combination with JS207 in subjects with solid tumor.

Conditions

Interventions

DRUG

7MW3711

7MW3711 will be administered as IV infusion.

DRUG

JS207

JS207 will be administered as IV infusion.

DRUG

Cisplatin

Cisplatin will be administered as IV infusion.

DRUG

Carboplatin

Carboplatin will be administered as IV infusion.

Sponsors & Collaborators

  • Mabwell (Shanghai) Bioscience Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-11
Primary Completion
2027-12-31
Completion
2029-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07466160 on ClinicalTrials.gov